AstraZeneca PLC (AZN)vsU.S. Physical Therapy, Inc. (USPH)
AZN
AstraZeneca PLC
$164.56
+1.23%
HEALTHCARE · Cap: $257.57B
USPH
U.S. Physical Therapy, Inc.
$84.84
+1.29%
HEALTHCARE · Cap: $1.24B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 7530% more annual revenue ($61.37B vs $804.27M). AZN leads profitability with a 17.0% profit margin vs 4.0%. AZN appears more attractively valued with a PEG of 1.19. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
USPH
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.2%
Fair Value
$195.81
Current Price
$164.56
$31.25 discount
Margin of Safety
+0.5%
Fair Value
$88.62
Current Price
$84.84
$3.78 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.3% — below average capital efficiency
4.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : USPH
The strongest argument for USPH centers on Price/Book.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : USPH
The primary concerns for USPH are Market Cap, Return on Equity, Profit Margin. A P/E of 489.2x leaves little room for execution misses. Thin 4.0% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while USPH is a value play — different risk/reward profiles.
USPH carries more volatility with a beta of 1.13 — expect wider price swings.
USPH is growing revenue faster at 8.5% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 46/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
U.S. Physical Therapy, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
US Physical Therapy, Inc. operates outpatient physical therapy clinics that provide preoperative and postoperative care and treatment for orthopedic-related disorders, sports-related injuries, preventive care, injured worker rehabilitation, and neurology-related injuries. The company is headquartered in Houston, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?